Researchers have announced a new Medicare pathway called the Medicare GLP-1 Bridge program, which will allow eligible Medicare Part D patients to access two weight management medications: Foundayo (orforglipron) and Zepbound (tirzepatide). This initiative marks a significant shift in Medicare’s coverage of obesity treatments, as historically, weight management medications have not been widely covered. The program aims to help the estimated 20 million Medicare patients who meet clinical criteria for these medications manage their weight effectively.

For individuals looking to age well, these medications can offer substantial benefits. Foundayo is a daily oral pill, while Zepbound is an injectable treatment, both designed for adults with obesity or those with overweight conditions accompanied by weight-related health issues. Clinical trials have shown that adults aged 65 and older can achieve meaningful weight loss—averaging around 13% with Foundayo and 14.1% with Zepbound when used alongside lifestyle changes. This weight reduction can lead to improvements in cardiovascular health and overall well-being, making these options particularly relevant for older adults seeking to maintain their health as they age.

The evidence supporting these medications comes from large Phase 3 clinical trials, which included thousands of participants. These trials demonstrated the efficacy and safety of both Foundayo and Zepbound in promoting weight loss and improving health markers. However, while the results are promising, they should be viewed as a foundation for further research, especially regarding long-term effects and broader population applicability.

If you’re a Medicare Part D patient interested in these medications, it’s essential to consult with your healthcare provider to determine eligibility under the new program. Once deemed eligible, you can start the process by obtaining a prescription and working with a pharmacy to manage the necessary authorizations. For more details, visit Lilly’s official site.